Trial record 20 of 57 for:    Open Studies | "Adenoviridae Infections"

Phase II Study of Adenovirus/PSA Vaccine in Men With Recurrent Prostate Cancer After Local Therapy APP21

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2014 by University of Iowa
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Lubaroff, David M, University of Iowa
ClinicalTrials.gov Identifier:
NCT00583752
First received: December 20, 2007
Last updated: January 22, 2014
Last verified: January 2014
  Purpose

The purpose of this study is to determine whether vaccination with the Ad/PSA vaccine will induce an anti-PSA immunity that will result in the destruction of the remaining prostate cancer cells.


Condition Intervention Phase
Recurrent Prostate Cancer
Biological: Adenovirus/PSA Vaccine
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study of Adenovirus/PSA Vaccine in Men With Recurrent Prostate Cancer After Local Therapy

Resource links provided by NLM:


Further study details as provided by University of Iowa:

Primary Outcome Measures:
  • PSA doubling-time response [ Time Frame: 18 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Serum PSA levels and immune response [ Time Frame: 18 months ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 70
Study Start Date: December 2007
Estimated Study Completion Date: July 2014
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm B
On Arm B, subjects will be started on androgen deprivation therapy (ADT) 14 days prior to beginning the vaccinations.
Biological: Adenovirus/PSA Vaccine
1x10E8pfu in Gelfoam subcutaneously on day 0, 30, 60
Experimental: Arm A
On Arm A, subjects can begin the three vaccinations immediately.
Biological: Adenovirus/PSA Vaccine
1x10E8pfu in Gelfoam subcutaneously on day 0, 30, 60

Detailed Description:

Subjects will be randomized to Arm A (vaccine only) or Arm B (androgen deprivation therapy plus vaccine). On Arm A, subjects can begin the three vaccinations immediately. On Arm B, subjects will be started on androgen deprivation therapy (ADT) 14 days prior to beginning the vaccinations.

Subjects will be vaccinated three times, each injection administered at 30-day intervals. Based upon our earlier clinical trial, the vaccine is considered safe and should not induce any major side effects. The investigators hope that vaccination with this PSA virus will cause the body to produce immunity to the PSA and that immunity will destroy any cell that produces PSA. Since the only cells left in the body that produce PSA will be the cancer cells, the investigators propose that the vaccination and ensuing anti-PSA immunity will kill the prostate cancer cells. Importantly, this treatment should not cause any major side effects as would treatment with anti-cancer drugs.

  Eligibility

Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men with prostate cancer who have received prior local therapy (radical prostatectomy or definitive radiation therapy) and have biochemical (PSA) relapse without evidence of radiographic or clinical metastatic disease.
  • For men who had prior prostatectomy, the surgery must have occurred at least 6 months prior to initiation of treatment.
  • For men who had prior definitive radiation therapy, radiation must have been completed at least 1 year prior to initiation of treatment.
  • Exhibit at least three separate rises in serum PSA, at least one month apart with differences >/= 0.03 ng/ml and a total PSA of >0.2 ng/ml.
  • Have a PSA doubling time of >/= 6 months if the baseline serum PSA was >2 ng/ml.
  • Negative bone scans.
  • Negative CT scans of abdomen and pelvis (no evidence of soft tissue lesions >/= 1 cm).
  • Scans must be obtained within 6 weeks of entry into the trial (initiation of treatment).
  • Written informed consent.
  • Age >/= 18 years.
  • Required laboratory values [obtained within 2 weeks of study entry (initiation of treatment)].
  • Serum creatinine </= 2.0 mg/dL
  • Adequate hematologic function: granulocytes >/= 1800 per mm3, platelets >/= 100,000 per mm3, WBC >/= 3700, and lymphocytes >/= 590.
  • Adequate hepatocellular function: AST <3x upper limit of normal and bilirubin <1.5 mg/dl (unless bilirubin elevation is consistent with Gilbert's syndrome).
  • PSA used as an eligibility criterion must be drawn within 42 days prior to injection number 1 and will be redrawn on Day 1 for use as a baseline value.

Exclusion Criteria:

  • Candidates for salvage radiation therapy unless the patient refuses.
  • Active or unresolved clinically significant infection.
  • Parenteral antibiotics <7 days prior to initiation of treatment.
  • Evidence of prior or current CNS metastases. Specific imaging is not necessary in the absence of signs or symptoms.
  • Co-morbid medical conditions which would result in a life expectancy (participation) of less than 1 year.
  • Patients with compromised immune systems; congenital, acquired, or drug-induced (immunosuppressive agents) will be excluded from the study. Use of prednisone at doses higher than 10 mg daily (or equipotent steroid doses) for more than 7 days within the last 3 months is not allowed.
  • No-pre-existing malignancies that required treatment within the past 5 years except for basal or squamous cell cancers of the skin.
  • Prior systemic therapies for prostate cancer not allowed (hormonal therapy, including but not limited to LHRH agonists, antiandrogens, ketoconazole or chemotherapy - mitoxantrone/taxanes/estramustine, etc.) except when patients stopped hormone therapy two or more years prior to enrollment and currently have normal testosterone levels; patients in Arm B, undergoing androgen depletion therapy during the vaccination will be eligible.
  • Prior participation in any vaccine studies for non-infectious diseases.
  • The inability to understand the language and the clinical protocol.
  • Allergy or religious objection to pork products; Gelfoam is produced from pork.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00583752

Contacts
Contact: David M Lubaroff, PhD 319-335-8423 david-lubaroff@uiowa.edu
Contact: Pamela Zehr, RN 319-353-8914 pamela-zehr@uiowa.edu

Locations
United States, Iowa
Holden Comprehensive Cancer Center Recruiting
Iowa City, Iowa, United States, 52242
Contact: David M Lubaroff, PhD    319-335-8423    david-lubaroff@uiowa.edu   
Contact: Pamela Zehr, RN    319-353-8914    pamela-zehr@uiowa.edu   
Principal Investigator: David M Lubaroff, PhD         
Sponsors and Collaborators
University of Iowa
Investigators
Principal Investigator: David M Lubaroff, PhD University of Iowa
  More Information

Publications:
Responsible Party: Lubaroff, David M, Professor, University of Iowa
ClinicalTrials.gov Identifier: NCT00583752     History of Changes
Other Study ID Numbers: 200605706, PC061667/1
Study First Received: December 20, 2007
Last Updated: January 22, 2014
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board
United States: Federal Government

Keywords provided by University of Iowa:
prostate cancer
vaccine
immunotherapy

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms

ClinicalTrials.gov processed this record on October 23, 2014